Prosecution Insights
Last updated: November 04, 2026
Application No. 17/311,633

METHODS AND PRODUCTS FOR TREATING FOLIC ACID DEFICIENCY AND MORNING SICKNESS

Final Rejection §103
Filed
Jun 07, 2021
Priority
Dec 08, 2018 — provisional 62/777,099 +1 more
Examiner
SIMMONS, CHRIS E
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aphios Corporation
OA Round
5 (Final)
34%
Grant Probability
At Risk
6-7
OA Rounds
0m
Est. Remaining
54%
With Interview

Examiner Intelligence

Grants only 34% of cases
34%
Career Allowance Rate
235 granted / 689 resolved
-25.9% vs TC avg
Strong +20% interview lift
Without
With
+19.8%
Interview Lift
resolved cases with interview
Typical timeline
4y 1m
Avg Prosecution
43 currently pending
Career history
729
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
46.1%
+6.1% vs TC avg
§102
12.0%
-28.0% vs TC avg
§112
26.1%
-13.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 689 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1-11 and 14-21 are pending. Claims 1-10 are withdrawn. Therefore, Claims 11 and 14-21 are presented for examination. Election/Restriction Applicant elected without traverse Invention II (method for treating morning sickness) and a dosage form comprising Vitamin B-9 as the specific folic acid, and 6-gingerol as the specific gingerol in the reply filed on April 20, 2024. Claims 11 and 13-20 read on the elected species. Prosecution on the merits will be restricted to the claimed species if no generic claim is finally held to be allowable. Priority This application is a 371 national stage application of PCT/US2019/064744 filed on December 05, 2019. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering obj4ective evidence present in the application indicating obviousness or nonobviousness. A. Rejection maintained - Claims 11 and 13-20 are rejected under 35 U.S.C. 103 as being unpatentable over Fazylov (WO 2015/080623 A1) (pub. June 2015; effect. filed November 2014) as evidenced by English translation of WO2015/080623 A1 (pub. June 2024) in view of Roy et al. (Ind. Eng. Chem. Res. 1996, 35, 607-612) and Perrin et al. (US 2013/0011377 A1) (pub. January 2013; effectively filed July 2011). Claimed invention Claim 11 is drawn to a method of treating morning sickness in a pregnant subject by administering a dosage form comprising: a folic acid selected from a group of natural and synthetic forms of Vitamin B-9, and a gingerol composition, comprising one or more compounds selected from the group consisting of 6-gingerol, 8-gingerol, 10-gingerol, 12-gingerol, 6-shogaol, 8-shogaol, and 10-shogaol, wherein the gingerol composition is produced using supercritical, near-critical or critical carbon dioxide extraction conditions; the dosage form comprises an oil base; the folic acid is dispersed as a solid in an oil base; the gingerol composition is dissolved in the oil base; and the oil base is contained in a gel capsule. Prior art Fazylov teaches a method for preparing tableted vitamin complexes for the prevention of nausea and vomiting during pregnancy. See English translation, e.g., paragraphs [0001]-[0002]. Fazylov teaches that vitamins help reduce the intensity of unpleasant manifestations of early pregnancy such as nausea and vomiting. See, e.g., paragraph [0004]. Fazylov teaches that the composition of the prepared tablets comprises folic acid and ginger. See, e.g., paragraphs [0010], [0011] and [0013]. Ginger is obtained from crushed dried roots (rhizomes) of cultivated ginger Zingiber Officinale and concentrated and dried in a vacuum spray dryer. See, e.g., paragraph [0042]. Fazylov also teaches that “gingerol” is an active substance in ginger and contains the resins “gingerol, zingerol, paradol, shogaol, etc.” and improves digestion and metabolism. See, e.g., paragraphs [0042]-[0043]. Folic acid, also known as folacin or Vitamin B9, is essential for fetal development and “[d]uring gestation, folate-dependent processes include growth of the fetus, uterus, placenta and mammary glands, as well as an increase in the number of red blood cells…Thus, during pregnancy the need for this vitamins increases sharply”. See, e.g., paragraph [0045]. Fazylov further teaches that folic acid, vitamin B6, a pharmacologically acceptable source of calcium, dry extract of ginger roots and other adjuvants/excipients are mixed in dry form and mixed with a binder in the form of a solution. The mixture is subjected to wet granulation, dried and sieved in order to obtain the resulting dry granules. See, e.g., paragraphs [0049]-[0050]. The product can be prepared in the form of a solid dosage form such as granules, tablets, and capsules. See, e.g., paragraph [0040]. In Example 4, Fazylov teaches a method to prepare granules comprising said 0.7 mg of folic acid, 20 mg of Vitamin B6, 40 mg of dry ginger root extract, 200 mg of calcium and other additional excipients. The granules containing a dusting agent are used to fill hard gelatin capsules. The capsules were tested on subjects and “showed excellent tolerability and a significant improvement in well-being with nausea, and elimination of gag reflexes”. See, e.g., paragraphs [0087]-[0098]. The method as taught by Fazylov reads on the instant claims as presented below: Claim 11, directed to a method of treating morning sickness comprising administering a dosage form comprising an effective amount of a folic acid with an effective amount of a gingerol composition to suppress nausea and/or gastric distress. The instant specification defines the phrase “morning sickness” as a condition in which pregnant women experience nausea especially in the first trimester of pregnancy. See, paragraph [0004]. The specification also defines that the extract of the ginger rhizome, Zingiber Officinale, is “associated with one or more of the following 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol.” See, Specification, paragraphs [0025] and [0051]. Fazylov teaches that the composition of the prepared tablets comprises folic acid and the extract of cultivated ginger Zingiber Officinale, which comprises resins “gingerol, zingerol, paradol, and shogaol”. See, e.g., paragraphs [0011]-[0025] and [0042]-[0043]. Thus, the extract encompasses 6-gingerol, 8-gingerol, 10-gingerol, and 6-shogaol. Fazylov teaches a method for preparing tableted vitamin complexes for the prevention of nausea and vomiting during pregnancy. While Fazylov teaches compositions containing a folic acid and a gingerol composition, Fazylov does not teach the method, wherein: said gingerol composition is produced under supercritical, near-critical or critical carbon dioxide conditions; said dosage form has an oil base, the folic acid is dispersed as a solid suspension in said oil base and said gingerol composition is dissolved in said oil base, as claimed in claim 11; or said oil base is held in a gel cap. According to MPEP §2141(III), one of the rationales in the KSR decision states “(C) Use of known technique to improve similar devices (methods, or products) in the same way”. KSR, 550 U.S. at 418, 82 USPQ2d at 1396. Regarding 1) gingerol composition produced under supercritical, near-critical or critical carbon dioxide conditions: Roy et al. reported a process for the supercritical carbon dioxide (sc-CO-2-) extraction of oil from ginger root as a function of solvent flow rate, particle size, temperature, and pressure. See title; p. 607, second column. Supercritical fluid extraction has received increasing attention in a variety of fields due to the following features: (a) supercritical fluids provide high solubility and improved mass-transfer rates; (b) operation can be manipulated by changing the pressure or temperature. Carbon dioxide is used as the supercritical fluid mainly because it is a safe, noncombustible, inexpensive, odorless, colorless, tasteless, nontoxic, and readily available solvent. Its low viscosity enables it to penetrate the matrix to reach the material being extracted, and its low latent heat of evaporation and high volatility mean that it can be easily removed without leaving a solvent residue. By varying the temperature and pressure of the CO2 during extraction, the flavor or odor components can be selectively extracted. See Table 1 for the properties of CO2. See p. 607, 1st column. Ginger is one of the major spices with widespread uses in foods, beverage, and medicine. See p. 607, 1st column. Thus, Roy et al. teach the preparation of ginger extract using a known technique with high solubility and improved mass-transfer rates that can be manipulated as desired by changing the pressure or temperature. The supercritical CO2 extraction technique is used because it involves implementing CO2 as a known safe, noncombustible, inexpensive, odorless, colorless, tasteless, nontoxic, and readily available solvent. Therefore, a person having ordinary skill in the art would have been motivated to obtain ginger extract using a known supercritical CO2 extraction technique because the technique is known to have high solubility and improved mass-transfer rates that can be manipulated as desired by changing the pressure or temperature. The POSA would have further recognized that the solvent, CO2, a safe, noncombustible, inexpensive, odor-less, colorless, tasteless, nontoxic, and readily available. The POSA would have had a reasonable expectation of success that the ginger extract can be obtained with a known technique used to extract components from ginger root for medicinal use. Regarding 2) the dosage form has an oil base, the folic acid is dispersed as a solid suspension within the oil base and said gingerol composition is dissolved in said oil base, and 3) said oil base is held in a gel capsule: Perrin et al. teach a method of administering compositions for nutritional supplementation in subjects in physiologically stressful states, such as during pregnancy, lactation, or in need thereof. See, e.g., paragraph [0002]. The compositions would include vitamins that “can be used to supplement the nutritional deficiencies observed in patients throughout physiologically stressful states, which, in certain embodiments of the present invention, include prenatal, pregnant and breast-feeding women”. See, e.g., paragraph [0010]. Perrin et al. teach that patients experiencing nausea may have difficulty swallowing nutritional supplements. Due to the soft and elastic nature, administering gel caps improves the patient compliance since they are easier to swallow. See, e.g., paragraphs [0008]-[0009]. The compositions further include pharmaceutically acceptable carriers, which include “binders, diluents, lubricants, glidants, colorants, emulsifiers, disintegrants, starches, water, oils, alcohols, preservatives, and sugars…"pharmaceutically acceptable carriers" refers to dosage forms such as capsules, caplets, gel-caps used with, for example, the compositions of the present invention… "pharmaceutically acceptable carriers" in gel-caps may be in for example, liquid or oil form. See, e.g., paragraph [0035]. Perrin et al. further teaches that the vitamins include vitamins B9 (folic acid) and B6. See, e.g., paragraphs [0005]. Perrin et al. teach a known technique of preparing and administering gel caps since they improve the patient compliance and much easier to swallow, especially for patients experiencing nausea. Perrin et al. further teach adding an oil base as an additional pharmaceutically acceptable carrier in order to improve the compositions of the gel caps for nutritional supplementations in subjects in physiologically stressful states, such as during pregnancy, lactation, or in need thereof. Additionally, Fazylov teaches that the composition comprising folic acid, dry extract of ginger roots and other adjuvants/excipients are combined in dry form and mixed with a binder in the form of a solution. The mixture is further subjected to wet granulation and the solid dosage form can be prepared in the form of granules, tablets, and capsules. Therefore, a person having ordinary skill in the art would have been motivated to prepare gel caps comprising folic acid and ginger roots, and further include an oil base as an excipient to dissolve or disperse said vitamins. The person of ordinary skill in the art would have had a reasonable expectation of success that the prepared gel capsules comprising the oil base will be much easier to swallow for patients suffering from morning sickness. Regarding Claim 14, Fazylov teaches that ginger is obtained from crushed dried roots (rhizomes) of cultivated ginger Zingiber Officinale. See, e.g., paragraph [0042]. With respect to Claims 15-17, Fazylov teaches that folic acid, vitamin B6, a pharmacologically acceptable source of calcium, dry extract of ginger roots and other adjuvants/excipients are mixed in dry form and mixed with a binder in the form of a solution. The mixture is subjected to wet granulation, dried and sieved in order to obtain the resulting dry granules. See, e.g., paragraphs [0049]-[0050]. The product can be prepared in the form of a solid dosage form such as granules, tablets, and capsules. See, e.g., paragraph [0040]. Thus, the resulting mixture would contain folic acid powder that is wetted by the gingerol composition, and prepared in the form of tablets and capsules. Regarding Claim 18, Fazylov teaches that folic acid and dry extract of ginger roots are mixed in dry form and mixed with a binder in the form of a solution. See, e.g., paragraph [0049]. Regarding Claim 19, Fazylov teaches Example 4, wherein 700 mcg (0.7 mg x 1000 mcg/1 mg = 700 mcg) of folic acid is present. With respect to Claim 20, Fazylov teaches ginger extract present at 40 mg. See 0090. This falls within the amount range, i.e., “20-40 mg”, disclosed in the instant specification as effective for the purposes of the invention. See Specification, 0027. Thus, the 40 mg gingerol extract in the Fazylov reference is present in amounts effective to for the invention including effective to promote hematopoiesis. Response to arguments Applicant argues that Fazylov teaches a fundamentally different formulation strategy because Fazylov uses conventional extraction, granulation, drying and tablet-forming techniques. However, the rejection does not rely on Fazylov for the claimed carbon dioxide extraction conditions or oil-based gel cap formulation. In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Roy supplies the teaching of known use of super critical carbon dioxide extraction (SCCO2) of ginger. Thus, Applicant’s argument against Fazylov alone rather than the combination of teachings is not persuasive. Applicant’s assertion that Fazylov teaches away from the claimed invention because it teaches other known extraction technique is not persuasive. The mere disclosure of one suitable preparation techniques does not constitute a teaching away. Applicant’s argument regarding the particular oil-phase arrangement is not persuasive. Perrin teaches oil-containing prenatal gelcaps and teaches the active may be present in the liquid carrier in either a dissolved or suspended state. It would have therefore, been obvious to formulate the modified Fazylov composition according to Perrin’s known gelcaps technique, with the oil-soluble gingerol composition dissolved in the oil phase and the folic acid in dispersed therein as a solid suspension. Applicant’s assertion regarding preservation of native gingerol profiles, reduced degradation, improved tolerability, stability, and bioavailability are not persuasive because these asserted advantages are not limitations of Claim 11, nor has Applicant established unexpected results commensurate in scope with the claim. Therefore, the rejection is deemed to still be proper and is, therefore, maintained. B. Rejection maintained - Claims 21 is rejected under 35 U.S.C. 103 as being unpatentable over Fazylov (2015) as evidenced by English translation of WO2015/080623 A1 (2015) in view of Roy et al. (Ind. Eng. Chem. Res. 1996, 35, 607-612) (pub. 1996) and Perrin (2013), as applied to Claims 11 and 13-20, taken further in view of Shao et al. (“Quantitative analysis of ginger components in commercial products using liquid chromatography with electrochemical array detection.” J Agric Food Chem. 2010 Dec 22;58(24):12608-14. doi: 10.1021/jf1029256. Epub 2010 Nov 23. PMID: 21090746; PMCID: PMC3446752.) Claimed invention Claim 21 limits claim 11, wherein the gingerol composition has a ratio of 6-shogaol to 6-gingerol of 0.04 to 0.40. Prior art Fazylov teaches administering ginger extract containing gingerols and shogaols, including 6-gingerol and 6-shogaol, for treatment of nausea and vomiting during pregnancy. However, Fazylov does not expressly teach the claimed ratio of between the two agents. However, Shao recognizes the therapeutic usefulness of ginger extracts for nausea, headaches and colds and teaches conventional ginger extracts, including dries and processed ginger preparations that contain both 6-gingerol and 6-shogaol. See pp. 1-3. For example, Shao discloses quantitative concentrations of both 6-ginger and shogaol in commercially available ginger products, from which one can directly derive 6-shogaol : 6-gingerol ratios between 0.19 and 0.40, which overlap the claimed range of 0.04-0.40: Sample 6-gingerol (mg/100g) 6-shogaol (mg/100g) 6-shogaol / 6-gingerol (mg/100g) #5 123.07 35.08 0.285041034 #8 277.51 111 0.399985586 #9 737.4 145.62 0.197477624 #10 554.87 115.67 0.208463244 #11 772.33 149.54 0.193621897 See Table 4 at p. 17. A person of ordinary skill in the art (POSA) would have found it obvious to obtain a gingerol composition having a 6-shogaol : 6-gingerol ratio of 0.04 to 0.40 because Fazylov teaches administering ginger extracts for the treatment of nausea and pregnancy that contain both gingerols and shogaols, including 6-gingerol and 6-shogaol, while Shao teaches that the relative amounts of 6-gingerol and 6-shigaol in ginger extracts vary depending on known processing and extraction conditions that are provided in already known and commercially available ginger products that may be useful for nausea and headaches. The POSA would have had a reasonable expectation that a ginger extract having the makeup of either one of the ginger extract products of Shao (e.g., #5, #8, #9, #10, #11, etc.) can be used to provide ginger extract for treating nausea. The POSA would have found it obvious that controlling or selecting the relative proportions of known active ginger constituents would occur through routine selection of already known extraction methods including those used for commercially available ginger extract products. Response to arguments Applicant arguments rely on those made above and have been sufficiently addressed above. Conclusion No claims are allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRIS E SIMMONS whose telephone number is (571)272-9065. The examiner can normally be reached M-F: 9:30-6:00p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H. Alstrum-Acevedo can be reached on (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRIS E SIMMONS/Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Show 4 earlier events
Jun 19, 2025
Request for Continued Examination
Jun 24, 2025
Response after Non-Final Action
Jul 28, 2025
Final Rejection mailed — §103
Nov 28, 2025
Request for Continued Examination
Dec 03, 2025
Response after Non-Final Action
Feb 24, 2026
Non-Final Rejection mailed — §103
May 26, 2026
Response Filed
Aug 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760036
INHIBITORS OF KIF18A AND USES THEREOF
1y 2m to grant Granted Oct 13, 2026
Patent 12746285
METHODS OF ACTIVATING CELLS VIA PTP 1B INHIBITION
5y 10m to grant Granted Sep 29, 2026
Patent 12708676
PHOSPHATE COMPOUNDS FOR DETECTING NEUROLOGICAL DISORDERS
3y 4m to grant Granted Aug 18, 2026
Patent 12692266
SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND
1y 0m to grant Granted Jul 28, 2026
Patent 12643846
PRODRUGS OF ITACONATE AND METHYL ITACONATE
4y 1m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7
Expected OA Rounds
34%
Grant Probability
54%
With Interview (+19.8%)
4y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 689 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month